Priority essential medicines: identifying products. Dr Suzanne Hill September 2010
|
|
- Ernest Homer Gilmore
- 6 years ago
- Views:
Transcription
1 Priority essential medicines: identifying products Dr Suzanne Hill September 2010
2 The problem looks like this
3 Robertson, Forte, Trapsida & Hill. Bull WHO 2009
4 Robertson, Forte, Trapsida & Hill. Bull WHO 2009
5 Or this
6 WHO-UNICEF Plan, 2006 Work on a global project to make paediatric medicines a priority: Add missing essential formulations to the Model list in 2007; advise on doses Develop EML for children (2007-8) Update treatment guidelines (2007-9) Develop paediatric prescribing information a formulary Develop effective methods for provision of information at the point of care Collaborate with regulatory authorities to encourage appropriate drug development and approval processes in all regulatory authorities Develop quality standards for paediatric medicines Advocate for the development of paediatric medicines by the industry Develop a system for enhancing safety monitoring of medicines in children Provide guidance on procurement and supply of paediatric medicines
7 Essential medicines for children World Health Assembly Resolution 'Make Medicines Child Size' Normative work, research needs Medicines for specific conditions Specifications for dosage forms Improving use of medicines in children National implementation
8 Preliminary consultation September 6-7 Participants from academia, procurement, donors, industry, other stakeholders Review of possible priority essential medicines for children Identify existing products that can be used Identify what is mssing Next steps
9 principles To treat: burden of disease, based on current treatment guidelines Clinical approach Weight based dosing for preference Consideration of different prescribers Strategies to enhance adherence Simplified dosing regimens Technology feasible Consideration of regulatory issues
10 Background Main burden of disease in children Neonatal infections Diarrhoea Pneumonia Malaria HIV TB
11 Global Causes of Child Deaths Black et al. Lancet, 2010 WHO. The World Health Statistics 2010 Black et al. Lancet, % of under five deaths are associated with undernutrition
12 Diarrhoea Medicine Form and strength Pack size Regimen ORS As specified (low osmolarity) 1 litre, 200 and 500 ml According to the dehydration status/guidelines Zinc Sulphate 10 or 20 mg FSOD 10 of either Once daily for 10 days NOTE : combination product would be appropriate
13 Pneumonia - Low HIV setting Category Medicine Form and strength Pack size Regimen Pneumonia (Fast breathing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Severe pneumonia (Chest Indrawing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Very severe pneumonia (danger signs) Oxygen, Ampicillin + gentamicin or ceftriaxone Cylinder/oxygen concentrators -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Variable Pack?? Single dose As needed Variable daily x 10 days mg/day 5 days NOTE: cotrimoxazole may be an alternative for pneumonia/fast breathing
14 Pneumonia: High HIV setting Category Medicine Form and strength Pack size Regimen Pneumonia (Fast breathing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Severe pneumonia (Chest Indrawing) Ampicillin + gentamicin or ceftriaxone -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Pack?? Single dose Variable daily x 10 days mg/day 5 days Very severe pneumonia (danger signs) Oxygen, Ampicillin + gentamicin or ceftriaxone Cylinder/oxygen concentrators -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Variable Pack?? Single dose As needed Variable daily x 10 days mg/day 5 days
15 Malaria Category Medicine Form and strength Pack size Regimen Malaria (uncomplicated) Artemeter +Lumefantrine (FDC) Artesunate + amodiaquine (FDC) Variable FSOD see treatment guideline For 3 day treatment 6x1 & 6x2 (30 blisters per box) 3 (25 blisters per box) Daily or twice daily x 3 days Malaria (severe or pre-referral) Artesunate Quinine hydrochloride 60 mg Injection 152 mg/ml injection?50/pack 100 ampoules/pack 2.4 mg/kg iv, 3 doses, then daily; 20mg infusion then 10mg/kg 8 hrly Artesunate rectal 50, 100, 200 mg Suppositories 6 per pack 10 mg/kg dose
16 HIV Category Medicine Form and strength Pack size Regimen HIV treatment AZT+3TC+NVP (< 3 years) AZT+3TC+EFV (>3 years) mg+50 mg FDC tablet, scored the 2nd one not available 30 days Once or twice daily HIV - Prophylaxis Isoniazid Cotrimoxazole 100 mg TMP 80+SMX 400mg; TMP 20+SMX 100 mg 30 days 30 days 10 mg/kg mg TMP /day age related doses
17 HIV ARV Prophylaxis Category Medicine Form and strength Pack size Regimen Breastfeeding population NVP 15mg once daily (10mg for low birth weight) Strength?? Form?? 30 days Variable according to weight and age Daily from birth until one week after all exposure to breastmilk Non breastfeeding population AZT or NVP 15mg twice daily or 15 mg once daily Strength?? Form?? 15 days? 45 days Variable according to weight and age For 4-6 weeks All exposed infants AZT or NVP 15mg twice daily or 15 mg once daily Strength?? Form?? 15 days? 45 days Variable according to weight and age For 4-6 weeks
18 Neonates Category Medicine Form and strength Pack size Regimen Neonatal sepsis Ampicillin + gentamicin or ceftriaxone Procaine penicillin? -500 mg or 1 G - 20 mg /ml 500 mg or 1 G?? Single dose Single dose -50 mg/kg x2 doses for 1 week and x3 doses for 2-4 wk mg/kg/day in 0-6 days and mg/kg in 7-59 days x mg/kg /day -40,000-60,000 units/kg/day Neonatal care Chlorhexidine Vitamin K Caffeine citrate 4% solution 1 mg/1 ml, 10 mg/ml 20mg/ml injection or oral liquid?? 500 ml Variable Variable Topical application mg x 1 at birth; 5mg/kg/day
19 Miscellaneous Category Medicine Form and strength Pack size Regimen Child survival Vitamin A 100,000 units capsule variable 100,000 units every 6 months Pain Paracetamol Variable FSOD 5-10 days supply 15 mg/kg 4-6 hours Morphine 10 mg oral dosage form 5 days Variable every 6 hours 10m/ml injection
20 TB Category Medicine Form and strength Pack size Regimen Treatment intensive phase, 2 months Isoniazid Rifampicin Pyrazinamide ethambutol 4 component FDC, flexible oral solid dosage form containing days In this does, weight based dosing, once daily Or product with same ratio Treatment, continuation phase, 4 months Isoniazid Rifampicin Pyrazinamide 3 component FDC, flexible oral solid dosage form containing Or 2 component FDC, flexible oral solid dosage form
21 FULL ASSET PROFILE: Amoxicillin Attribute Worst case BASE CASE Best case Comment Summary Profile Description Objective / Rationale Develop a dispersible amoxicillin product for pediatric patients in the developing world target age range? Dosing Regimen Twice daily Weight based dosing: 2-4kg 0.5 x 250mg tablet bd 5-9kg 1 x 250mg tablet bd 10-20kg 1 x 500mg tablet bd 21-30kg 2 x 500mg tablet bd Presentation (form and pack size) sachet? Taste-masked, dispersible tablet. Pack size 10 meltaway formulation flavor preferences? Can it be given in breast milk? Strength 250mg or 500 mg Both in packs of 10 Duration of Therapy Quality Standard Scoring 5 days SRA approval - WHO PQ, US FDA, or equivalent yes Packaging Blister packs? Any labeling requirements? Stability/shelf life Estimate Year of Launch Selling Price XX XXX XX Royalties 2 years minimum, zone 4 stability, store at or below X C 3 or more years no cold chain requirements *Prices taken from WHO/UNICEF Sources and prices of selected medicines for children Median price (USD) per dose, unless otherwise stated. XXX Current amoxicillin price*: 250 mg dispersible 0,022; 500 mg capsule 0,032; 250 mg capsule 0,018 will developing company get to charge "reasonable" or get other market advantage?
22 Weight based dosing Examples Antiretrovirals First line treatments for TB Amoxicillin
23 Amoxicillin/ cotrimoxazole weight (kg) amoxicillin bd (at least 50mg per day) cotrimoxazole bd (TMP at least 8mg/day) 250 total mg/kg per day 500 total mg/kg per day (TMP) total mg/kg per day (TMP) total per day tabs per dose tabs per dose tabs per dose tabs per dose
24 Strategies to enhance adherence Packaging and labelling Artemether-lumefantrine What pack size for long term treatments? TB, HIV What approach will work for community based administration of antibiotics?
25 Technology/dosage form Oral versus not Stable, long shelf life Avoiding liquids Flexible oral solid dosage form Simplified dosing schedules, weight based dosing
26 Regulatory questions - product Does a change of doing regimen need a change of label? Amoxicillin? What about pack size? 10 versus 21? What about different FDCs without an innovator? HIV, TB?
27 'Sure' ORS But with a smaller sachet and flavour, pack of 10 Zinc 20mg scored dispersible- with ORS ACT(s) Dispersible / FOSD dose optimised see WHO guidelines Artesunate Rectal, and injection (but better) HIV FDC (s) - see WHO guidelines Nevirapine, zidovudine Amoxicillin dispersible, scored 250 and 500, pack of 10 Oxygen TB FDCs next slide Analgesics paracetamol ( dispersible), morphine Vitamin A 100,000 IU
28 Work needed TB FDC correct component strength** Artesunate - injection and rectal mg dose range (10mg/kg) Caffeine citrate standard product, market readiness - 20mg/ml, liquid and injection Chlorhexidine solution, 4% regulatory pathway and patient pack Isoniazid / cotrimoxazole product strength not yet known for prophylaxis (HIV co pack?)
29 Problems -TB rifampicin: 15 mg/kg/d (10 to 20 mg/kg/day) isoniazid: 10 mg/kg/d (10 to 15 mg/kg/day) pyrazinamide: 35 mg/kg/d (30 to 40 mg/kg/day) ethambutol: 20 mg/kg/d (15 mg to 25 mg/kg/d) WANTED - Fixed Dose Combination (FDC) containing rifampicin 250 mg, isoniazid 150 mg, pyrazinamide 400 mg, and ethambutol 250 mg Dose: 0.5 to 2.0 'tablets' per day, 5-30 kg
30 Problems - TB
31 Solutions needed
32 Clinical evidence needed Optimised dosing regimens for Vitamin K? Gentamicin Ampicillin Procaine penicillin Ceftriaxone
33 Priority essential medicines for children Priority Essential Necessary
34 Priority essential medicines for children Necessary Essential Priority
35 Where is my essential medicine?
Medicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
More informationSources and Prices of Medicines for Children.
Sources and Prices of Medicines for Children. Consultation on Priority Essential Medicines for Child Survival 6th-7th September, 2010 Copenhagen, Denmark 1 Sources and Prices of Selected Medicines for
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
More informationRationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationUpdate on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland
Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised
More informationThe International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
More informationIl programma dei farmaci essenziali dell OMS, la nuova lista marzo Suzanne Hill Department of Medicines Policy and Standards WHO
Il programma dei farmaci essenziali dell OMS, la nuova lista marzo 2007 Suzanne Hill Department of Medicines Policy and Standards WHO Essential medicines 30 years on Outline A review of 30 years of essential
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationApplication for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion...
More informationStrategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children
Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Dr. Mark W. Young Senior Health Specialist UNICEF Programme Division New York September 24,
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More informationCURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
More informationPaediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
More informationThe pathway to better medicines for children
The pathway to better medicines for children As the World Health Organization counts down to 2015 and the Millennium Development Goal to reduce under five-year-old mortality by two-thirds, we reflect on
More informationExisting and most needed paediatric ARV formulations
Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0
More informationJOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN
JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim
More informationGuidelines for management of suspected sepsis in young infants where referral is not possible
Guidelines for management of suspected sepsis in young infants where referral is not possible Kenya Paediatrics Association Conference, 26-29 April 2016, Eldoret Kenya 1 Kenya Paediatrics Association Conference,
More informationCHILDREN S MEDICINES IN UGANDA
Medicines for Children CHILDREN S MEDICINES IN UGANDA An investigation into availability and factors impacting access INTRODUCTION The continuous availability of affordable medicines for children is necessary
More informationThe Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations
Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationWhat essential medicines for children are on the shelf?
Jane Robertson et al. Availability of essential children s medicines What essential medicines for children are on the shelf? Jane Robertson, a Gilles Forte, b Jean-Marie Trapsida c & Suzanne Hill b a University
More informationClinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, 2005 User s Manual Index 1. Overview 2. Scale-Up Assumptions 3. Procurement Assumptions 4. Clinical Assumptions 5.
More informationIntegrated Community Case Management (iccm) and the role of pneumonia diagnostic tools
Integrated Community Case Management (iccm) and the role of pneumonia diagnostic tools Theresa Diaz MD MPH Senior Health Advisor Health Section UNICEF, NY (on behalf of Mark Young) Strong need for community-based
More informationFrequently Asked Questions on Zinc and Suggested Responses
Last edited: September 27, 2012 Zinc Treatment of Childhood Diarrhea Frequently Asked Questions Diarrhoea still remains a leading cause of morbidity and mortality in developing countries. Every year more
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationDr. Rai Muhammad Asghar Associate Professor of Pediatrics Benazir Bhutto Hospital Rawalpindi
Dr. Rai Muhammad Asghar Associate Professor of Pediatrics Benazir Bhutto Hospital Rawalpindi MANAGEMENT OF THE CHILD WITH COUGH OR DIFFICULT BREATHING Global Burden * Commonest cause of death * 2 million
More informationPediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
More informationDepartment of Pediatrics RGH Rawalpindi Medical College
Department of Pediatrics RGH Rawalpindi Medical College COUGH OR DIFFICULT BREATING Dr. Rai Muhammad Asghar Associate Professor of Pediatrics department RGH Rawalpindi MANAGEMENT OF THE CHILD WITH COUGH
More informationAdherence to case management guidelines of IMCI by health care workers in Tshwane
Adherence to case management guidelines of IMCI by health care workers in Tshwane S Afr J Child Health 2015;9(3):89-92. DOI:10.7196/SAJCH.7959 Mphele Mulaudzi UPdate 4 March 2016, Menlyn Introduction Integrated
More informationChild Health Services Tanzania Service Provision Assessment (TSPA)
Child Health Services 2014-15 Tanzania Service Provision Assessment (TSPA) Background of Child Health (2010 TDHS) Availability of Services Service Readiness Management Practices and Training Observations
More informationMMV s Access & Product Management Strategy
MMV s Access & Product Management Strategy Siem Reap, Cambodia 24-26 February 2015 George Jagoe, EVP, Access & Product Mgmt Defeating Malaria Together OUR MISSION to reduce the burden of malaria in disease-endemic
More informationINTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS FOR HIGH HIV SETTINGS
Department of Child and Adolescent Health and Development (CAH) INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS FOR HIGH HIV SETTINGS CHILD AGE 2 MONTHS UP TO 5 YEARS ASSESS AND CLASSIFY THE SICK CHILD Assess,
More informationBabies 1500g. Caffeine citrate. Sodium Acid Phosphate (1mmol/ml) Ferrous Fumarate (Galfer 140mg/5ml) Infloran. Abidec BMF
Babies 1500g Infloran Caffeine citrate BMF Sodium Acid Phosphate (1mmol/ml) Abidec Ferrous Fumarate (Galfer 140mg/5ml) Dose Half capsule BD 10mg/kg once daily (write as caffeine citrate) 2% BMF each feed
More informationNutrition Procurement Overview
Nutrition Procurement Overview RUTF Pre-tender Industry Consulation Copenhagen, 11-13 June 2018 Click to edit Master subtitle style Supply Division Structure (2018-2021) Director Deputy Director Programme
More informationNEW PNEUMONIA CASE MANAGEMENT GUIDELINES. By Andolo Miheso,Christine Wambugu, Sophie Ngugi, Warfa Osman (NCAHU MOH) & Ambrose Agweyu (KWT)
NEW PNEUMONIA CASE MANAGEMENT GUIDELINES By Andolo Miheso,Christine Wambugu, Sophie Ngugi, Warfa Osman (NCAHU MOH) & Ambrose Agweyu (KWT) Outline of the presentation: Overview of Child Health situation
More informationChallenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs. Presented by Shaffiq Essajee (CHAI, USA)
Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs Presented by Shaffiq Essajee (CHAI, USA) Optimize paediatric ARVs and shape the market PADO New drugs,
More informationMATERNAL, NEWBORN, AND CHILD HEALTH
MATERNAL, NEWBORN, AND CHILD HEALTH SESSION OBJECTIVES Introduction to GHSC-PSM Maternal, Newborn, and Child Health (MNCH) strategy and priorities Defining MNCH commodities Overview of historical and current
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationOverview of UNICEF engagement in health & supply. Supply Division, 27 September 2010
Overview of UNICEF engagement in health & supply Supply Division, 27 September 2010 Presentation outline Reaching MDGs with equity Priority interventions Introduction to UNICEF Supply Divisions work The
More informationHave new initiatives to improve availability made a difference?
Have new initiatives to improve availability made a difference? Evidence from the ARV field on changes in the pediatric medicines market Brenda Waning WHO/UNITAID 5 November, 2010 American Society of Tropical
More informationAntimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
More informationToolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES
Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES June 2008 Table of contents 1. Introduction... 2 2. Data sources... 2 Facility reporting systems...3 Key informant
More informationINITIATING ART IN CHILDREN: Follow the six steps
INITIATING ART IN CHILDREN: Follow the six steps STEP 1: DECIDE IF THE CHILD HAS CONFIRMED HIV INFECTION Child < 18 months: HIV infection is confirmed if the PCR is positive and the VL is more than 10,000
More informationANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL
ZIDOVUDINE (AZT, Retrovir ) Benefits of zidovudine: Zidovudine (ZDV) is an antiretroviral drug that slows the growth of the HIV virus. It has shown in a large randomized, multicentre study to decrease
More informationEssential Medicines: update on policies and standards
Essential Medicines: update on policies and standards Jane Robertson Technical Officer Health Technologies and Pharmaceuticals (HTP) WHO Regional Office for Europe Pharmaceutical sector is complex R&D
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationTB/HIV Monitoring & Advocacy Project Interview Tool
TB/HIV Monitoring & Advocacy Project Interview Tool This interview tool is based upon the Interim Policy on Collaborative TB/HIV Activities of the World Health Organization. 1 It is designed to help you
More informationInternational initiatives on extemporaneous dispensing
Partners meeting WHO, Geneva 21 22 November 2011 International initiatives on extemporaneous dispensing Tony Nunn and Mark Turner UK Medicines for Children Research Network University of Liverpool Industry
More information1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
More informationFigure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT)
Figure S1: Overview of PMTCT Options A and B Prevention of Mother to Child HIV Transmission (PMTCT) Option A: combined Antiretroviral therapy (ART) for all women meeting WHO 2010 criteria for initiation
More information18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa
A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop
More informationThe New National Guidelines. Feeding in the Context of HIV. Dr. Godfrey Esiru; National PMTCT Coordinator
The New National Guidelines (2010) for PMTCT and Infant Feeding in the Context of HIV Dr. Godfrey Esiru; National PMTCT Coordinator Presentation outline Evolution of the PMTCT guidelines in Uganda Rational
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationQ&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)
Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a
More informationAn innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria
UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More information5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationPaediatric ARV Procurement Working Group Progress Review at 31 December 2015
Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Version 4 March 2015 Updated with complete 2015 data from version presented at the January 27 2016 PAPWG meeting PAPWG Reporting
More informationUNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1
Page 1 UNITAID AMDS Partners Meeting UNITAID 2013-2016 Strategy & 2013 Call for Letters of Intent Brenda Waning Geneva 7 May, 2013 UNITAID s Six Strategic Objectives SO1: Increase access to simple, point-of-care
More informationProduct Characteristics and Product Information Links between Quality and Clinical
Product Characteristics and Product Information Links between Quality and Clinical Regine Lehnert 8th Annual Prequalification Assessment Training (Quality), Copenhagen, 16-18th May 2016 A Good Medicinal
More informationDrug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand
Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.
More informationNew Directions on WHO ARV Guidelines 2018
New Directions on WHO ARV Guidelines 2018 Elaine Abrams Co-chair WHO Guidelines Development Group ICAP at Columbia University, New York Martina Penazzato Paediatric lead for the HIV Department World Health
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationPneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI
Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening
More informationPaediatric HIV Resistance. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal
Paediatric HIV Resistance Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Preliminary evaluation of referrals for Antiretroviral Therapy (ART)
More informationUNICEF and the 2030 agenda for Sustainable Development; Focus on Health
UNICEF and the 2030 agenda for Sustainable Development; Focus on Health Dr Claudia Vivas Torrealba, Health Specialist cvivas@unicef.org Health Section. Program Division Sep 2016 UNICEF Health Strategy
More informationCaring for sick children in the community: Experiences from Malawi. Humphreys Nsona IMCI Unit
Caring for sick children in the community: Experiences from Malawi Humphreys Nsona IMCI Unit Outline of the presentation Rationale for community case management of childhood illness (CCM) in Malawi Characteristics
More informationMaternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York
Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Copenhagen, Denmark 23 September 2013 Visit www.everywomaneverychild.org
More informationAntibiotic Protocols for Paediatrics Steve Biko Academic Hospital
Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Respiratory tract infections in children Uncomplicated URTI A child with a cold should not receive an antibiotic Paracetamol (15 mg/kg/dose
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 2015 C e n t r a l T B D i v i s i o n D i r e c t o r a t e G e n e r a l o f H e a l t h S e r v i c e s M i n i s t r y o f H e a l t h & F a m i l y
More informationQUESTIONS AND ANSWERS
QUESTIONS AND ANSWERS Common questions about treating diarrhoea with zinc and oral rehydration salts (ORS) SPACE FOR LOGO INTRODUCTION To treat childhood diarrhoea, the World Health Organization recommends
More informationObjectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)
Objectives Prevention of Mother-to-Child Transmission (PMTCT) Teen Club Community Partners Training Programme By the end of the session participants will be able to: 1. Identify factors affecting the transmission
More informationCCC ARV Dosing Recommendations for HIV-exposed infants Updated
USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for
More informationReport of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland
Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland Comments of the Malta Chamber of Pharmacists 15 th February 2008 The Malta Chamber
More informationCare of the HIV-Exposed Infant
Care of the HIV-Exposed Infant Use of Flipchart To promote quality and consistency of counseling Why use the counseling flipchart? To improve HIV-exposed infant outcomes through high quality counseling.
More informationManagement of Tuberculosis Training for Health Facility Staff. F: Manage Drugs and Supplies for TB. WORLD HEALTH ORGANIZATION Geneva
Management of Tuberculosis Training for Health Facility Staff F: Manage Drugs and Supplies for TB WORLD HEALTH ORGANIZATION Geneva WHO/CDS/TB/2003.314f Management of Tuberculosis Training for Health Facility
More informationIndustry Perspective on Formulation and Packaging Considerations
Industry Perspective on Formulation and Packaging Considerations Ron Ogilvie (Pfizer) EFPIA February 2012 1 Industry Perspective on Formulation and Packaging Considerations Provide an overview of formulation
More informationThe Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT
The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT Peter McDermott Managing Director, CIFF 19 th Board meeting, Geneva 6 th May 2009 Investment Criteria Measurable...change
More informationNutrition Update Severe acute malnutrition
Nutrition Update Assessing the nutritional status of children and the presence of anemia is an integral part of the IMCI ask, look and listen strategy. The risk of death from acute respiratory infection,
More informationINTRODUCTION. WHO/Christopher Black
INTRODUCTION WHO/Christopher Black 7 1. BACKGROUND In 2016, an estimated 2.1 million children younger than 15 years and 17.8 million women were living with HIV worldwide (1). Despite advances in antenatal
More informationMinistry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013
istry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013 Introduction The purpose of this report is to inform the istry of Health and all stakeholders of the stock levels in the country
More informationUNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS. November 3-4, WHO Headquarters, Geneva, EB Room
UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS November 3-4, 2004 WHO Headquarters, Geneva, EB Room Summary Background In 2003, more than 5 million people
More informationTechnical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults
Technical Guidance Note for Global Fund HIV Proposals TREATMENT - Antiretroviral Treatment-infants, children and adults May 2010 This technical brief is designed to provide key technical information to
More informationGlobal initiatives and priority products for MNCH
Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Copenhagen, Denmark 22 September 2014 Reductions in absolute numbers of child deaths The total
More informationPrequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
More informationAPRIL Key Findings: Overall. Key Findings: Availability
APRIL 2006 Key Findings: Overall o Medicines were more available in private pharmacies than in other sectors o Even for medicines on the Kenya Essential Drug List, 20 out of 28 of these had below 50% availability
More informationCodeine and Paracetamol in Paediatric use, an Update 5 th October 2013
Codeine and Paracetamol in Paediatric use, an Update 5 th October 2013 This guidance should be read in parallel to the detailed guidelines on pain management in children (APA guidelines) 2 nd edition.
More informationCategory and Product-level Procurement and Delivery Planning Guide
Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global
More informationA Layperson s Guide to Pediatric Formulation Development
A Layperson s Guide to Pediatric Formulation Development Karen C. Thompson PhD Senior Principal Scientist Preclinical Development Merck Research Laboratory West Point, Pennsylvania Martin J. Gartland PhD
More informationMedication Calculations - part 1
Medication Calculations - part 1 Learning Skills Introduction: Common calculations required in nursing include finding volumes needed for oral or injected doses and working out IV infusion flow and drip
More informationAccess to essential medicines 59
4. 59 4. 4.1 Introduction According to the WHO framework for health systems (1), a well-functioning health system ensures equitable access to essential medical products, vaccines and technologies of assured
More informationWHO/UNICEF JOINT STATEMENT
WHO/UNICEF JOINT STATEMENT CLINICAL MANAGEMENT OF ACUTE DIARRHOEA Two recent advances in managing diarrhoeal disease newly formulated oral rehydration salts (ORS) containing lower concentrations of glucose
More informationReview of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA
Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed
More informationDorothy Mbori-Ngacha UNICEF
THE DOUBLE DIVIDEND Action to improve survival of HIV exposed infected and uninfected children in the era of emtct and renewed child survival campaigns Dorothy Mbori-Ngacha UNICEF Outline The Double Dividend
More informationOutline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children?
Prevention of mother-to-child transmission of HIV Outline AimofPMTCT How HIV is transmitted to children Epidemiology of HIV in children How to reduce HIV transmission to children Guidelines Lars T. Fadnes
More informationWHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION
Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Name of the focal point in WHO submitting or supporting the
More information